
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded topical liquid containing kojic acid, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
No FDA-approved (NDA or ANDA) product containing kojic acid is listed. Products containing it are filed in the directory as over-the-counter monograph drugs, in liquid and lotion forms.
Liquid bases can be aqueous or nonaqueous, and USP <795> classifies the preparation by its water activity. Aqueous preparations carry shorter default beyond-use dates than nonaqueous ones. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Kojic acid is a tyrosinase-inhibiting skin lightening agent that compounding pharmacies prepare in topical creams, gels and serums by prescription.
Kojic acid is a natural compound made by Aspergillus fungi and formed during the fermentation of foods such as soy sauce and sake. It is a tyrosinase inhibitor: it binds the copper in tyrosinase, the enzyme that starts melanin production, so the skin makes less pigment where it is applied. It is also an antioxidant. No FDA-approved drug product contains kojic acid. It appears in cosmetics, where the Cosmetic Ingredient Review panel concluded it is safe at low concentrations, and peer-reviewed reviews describe its use for melasma, freckles, age spots and post-inflammatory hyperpigmentation, usually alongside other lightening agents. A prescriber might order compounded kojic acid combined with hydroquinone, glycolic acid or another agent in one prescription preparation, at a concentration not sold in cosmetics, or in a vehicle without fragrance. Compounded preparations are not FDA-approved and require a prescription.
Because no manufactured drug contains kojic acid, there is no FDA label and no boxed warning. The main side effect reported in reviews is irritant or allergic contact dermatitis, most often on sensitive skin. Long-term use may make skin more prone to sunburn, so use sun protection, and do not apply it to broken skin. Do not use kojic acid if you have reacted to it before. The International Agency for Research on Cancer places kojic acid in Group 3, not classifiable as to human carcinogenicity; animal tumor-promotion findings involved exposures the CIR panel considered unlikely from skin use. There is no FDA label statement on pregnancy or breastfeeding, so tell your prescriber if either applies. If redness, stinging or peeling develops, stop and talk to your prescriber or pharmacist.
Kojic acid (5-hydroxy-2-hydroxymethyl-4-pyrone) is a fungal metabolite that chelates copper at the tyrosinase active site, inhibiting the conversion of L-tyrosine in melanogenesis, with non-competitive inhibition of diphenolase activity reported for mushroom tyrosinase; it also scavenges free radicals. It is absorbed slowly through human skin, which the CIR used to argue that systemic levels stay below those associated with tumor promotion in rodents. The free acid is unstable in formulation, which led to esters such as kojic dipalmitate. No manufactured product is labeled for any indication; the CIR panel found it safe in cosmetics at low concentration with dermal sensitization and depigmentation as the endpoints of concern. Prescribers have ordered compounded kojic acid, usually with hydroquinone, glycolic acid or other depigmenting agents, for melasma and other hyperpigmentation; a 2024 review in Cosmetics summarizes comparative trials in which kojic acid combinations outperformed the same regimen without it, while kojic acid alone compared unfavorably with hydroquinone, and positions it for hydroquinone-intolerant patients and maintenance. Concentration, combination and vehicle are per prescriber. Monitor for contact dermatitis. Kojic acid is not a controlled substance.
Wash your hands. Apply the amount on your label to clean, dry skin using the applicator provided or a cotton swab. Let it dry before covering. Use an accurate measuring device if your label gives a volume. Keep it away from the eyes and avoid open flame if the solution contains alcohol. Wash your hands afterward.
Topical solutions are aqueous or alcohol based. Under USP <795>, a preserved aqueous solution usually carries a beyond-use date of up to 35 days; an unpreserved one 14 days refrigerated; a nonaqueous solution may carry up to 180 days. Keep the bottle tightly closed at room temperature, away from heat and flame, out of reach of children, and discard after the beyond-use date on your label.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.